PD-L1 antibody

Catalog No. ABIN7670558

This Mouse Monoclonal antibody specifically detects PD-L1 in ELISA (Detection). It exhibits reactivity toward Human.

Quick Overview for PD-L1 antibody (ABIN7670558)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-L1 antibody is un-conjugated

Application: ELISA (Detection)

Clone: 5A7

Product Details anti-PD-L1 Antibody

Purpose: PD-L1 Monoclonal Antibody(Detector)

Purification: Protein A/G Purification

Immunogen: Recombinant Human PD-L1 L1 protein expressed by Mammalian

Isotype: IgG2a

Application Details

Application Notes: ELISA Detector 0.1-0.4 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Sterile PBS , pH 7.4

Preservative: Without preservative

Handling Advice: Avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C Valid for 1 month or -20°C Valid for 12 months

Expiry Date: 12 months

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PD-L1

Background: CD274,B7H1,PDCD1L1,PDCD1LG1,PDL1,PD-L1,Programmed ceLL death 1 Ligand 1,B7 homoLog 1,PDCD1 Ligand 1,Programmed death Ligand 1,hPD-L1,Plays a critical role in induction and maintenance of immune tolerance to self.As a ligand for the inhibitory receptor PDCD1/PD-1,modulates the activation threshold of T-cells and limits T-cell effector response.Through a yet unknown activating receptor,may costimulate T-cell subsets that predominantly produce interleukin-10 (Il10).Can also act as a transcription coactivator: in response to hypoxia,translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC,leading to pyroptosis.The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system,thereby facilitating tumor survival.The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTls) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response,providing a rationale for cancer immunotherapy.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints